What amount sold does Axxess Compounding II, LLLP report in Form D filings?

The latest linked filings report $355K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Axxess Compounding II, LLLP's most recent SEC filing?

Axxess Compounding II, LLLP's most recent Form D filing was on 2014-11-06.

How many investors does Axxess Compounding II, LLLP have?

The most recent Form D filing lists 33 investor(s).

What type of securities does Axxess Compounding II, LLLP offer?

Axxess Compounding II, LLLP's SEC Form D filings indicate equity offerings.

Axxess Compounding II, LLLP

CIK: 0001595664·Pharmaceuticals·MISSOULA, MT·Limited Partnership·Founded 2012

Reported Sold

$355,000

Total Filings

Identified Offerings

Last Filed

Nov 6, 2014

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Nov 6, 2014Form D/A — Amendment

Reported sold: $355,000 · Target: $25,470,000

Rule 506(b)·33 investors

Changed: Reported amount sold, Offering target, Reported investors

Jan 29, 2014Form D — New notice

Reported sold: $250,000 · Target: $470,000

Rule 506(b)·22 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

No Revenues

Reported commissions across identified offerings

Amendment Rate

50%

Latest reported sold across 1 identified offering

$355,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Frances X Riegler

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 6, 2014	Amendment	$25,470,000	$355,000	33
Jan 29, 2014	New	$470,000	$250,000	22

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

EIKONOKLASTES THERAPEUTICS, INC.

Pharmaceuticals

Offering target: $18,638,880

Filed Oct 5, 2026